8,898 results match your criteria idiopathic arthritis

Atraumatic femoral head necrosis: a biomechanical, histological and radiological examination compared to primary hip osteoarthritis.

Arch Orthop Trauma Surg 2021 May 10. Epub 2021 May 10.

Department of Orthopaedic, Trauma and Plastic Surgery, Leipzig University, Liebigstr. 20, 04103, Leipzig, Germany.

Introduction: Atraumatic necrosis of the femoral head (AFHN) is a common disease with an incidence of 5000-7000 middle-aged adults in Germany. There is no uniform consensus in the literature regarding the configuration of the bone in AFHN. The clinical picture of our patients varies from very hard bone, especially in idiopathic findings, and rather soft bone in cortisone-induced necrosis. Read More

View Article and Full-Text PDF

Efficacy of home-based physical activity interventions in patients with autoimmune rheumatic diseases: A systematic review and meta-analysis.

Semin Arthritis Rheum 2021 Apr 16;51(3):576-587. Epub 2021 Apr 16.

Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil. Laboratory of Assessment and Conditioning in Rhematology, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil Av. Dr. Arnaldo, 455, ZIP code: 01246-903, Sao Paulo-SP, Brazil; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. Electronic address:

Introduction: Physical activity (PA) has been receiving increasing interest in recent years as an adjuvant therapy for autoimmune rheumatic disease (ARDs), but there is scarce information about the efficacy of home-based PA for patients with ARDs.

Objective: To perform a systematic review and meta-analysis on the efficacy of home-based physical activity (PA) interventions in improving health-related quality of life, functional capacity, pain, and disease activity in patients with ARDs.

Methods: Searches were performed in PubMed, Web of Science, Scopus, Cochrane, CINAHL database and Sport Discus. Read More

View Article and Full-Text PDF

Biomarkers of lipid metabolism in patients with juvenile idiopathic arthritis: relationship with disease subtype and inflammatory activity.

Pediatr Rheumatol Online J 2021 May 3;19(1):66. Epub 2021 May 3.

Department of Pediatrics, Universidade Federal de São Paulo, Rua Borges Lagoa, 802 - Vila Clementino, São Paulo, SP, CEP: 04038-001, Brazil.

Background: To describe the biomarkers of lipid metabolism in children and adolescents with polyarticular and systemic JIA and to relate them to diseases subtypes, diseases activity markers, and nutritional status.

Methods: A cross-sectional study including 62 JIA patients was performed. The following variables were evaluated: disease activity and medications used, body mass index, height for age (z-score), skin folds (bicipital, tricipital, subscapular and suprailiac), food intake based on three 24-h food recalls, lipid profile (total cholesterol (CT), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG) and non-HDL (N-HDLc), glycemia and insulin, erythrocyte sedimentation rate (ESR), ultrasensitive C-reactive protein (us-CRP) and apolipoproteins A-I and B (Apo A-I and Apo B). Read More

View Article and Full-Text PDF

Costs of hospital-associated care for patients with juvenile idiopathic arthritis in the Dutch healthcare system.

Arthritis Care Res (Hoboken) 2021 May 2. Epub 2021 May 2.

Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands.

Objective: This study aims to 1) quantify costs of hospital-associated care for juvenile idiopathic arthritis (JIA), 2) provide insights in patient-level variation in costs, and 3) investigate costs over time from the moment of JIA diagnosis. Results are reported for all JIA patients in general and by subtype.

Methods: This study is a single-center, retrospective analysis of prospective data from electronic medical records of children with JIA, aged 0-18 years between 1 April 2011 and 31 March 2019. Read More

View Article and Full-Text PDF

CD21CD27IgM Double-Negative B Cells Accumulate in the Joints of Patients With Antinuclear Antibody-Positive Juvenile Idiopathic Arthritis.

Front Pediatr 2021 16;9:635815. Epub 2021 Apr 16.

Pediatric Immunology, University Children's Hospital, Würzburg, Germany.

Juvenile idiopathic arthritis (JIA) encompasses a heterogeneous group of diseases. The appearance of antinuclear antibodies (ANAs) in almost half of the patients suggests B cell dysregulation as a distinct pathomechanism in these patients. Additionally, ANAs were considered potential biomarkers encompassing a clinically homogenous subgroup of JIA patients. Read More

View Article and Full-Text PDF

Reliability of activity monitors for physical activity assessment in patients with musculoskeletal disorders: A systematic review.

J Back Musculoskelet Rehabil 2021 Apr 27. Epub 2021 Apr 27.

IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.

Background: Activity monitors have been introduced in the last years to objectively measure physical activity to help physicians in the management of musculoskeletal patients.

Objective: This systematic review aimed at describing the assessment of physical activity by commercially available portable activity monitors in patients with musculoskeletal disorders.

Methods: PubMed, Embase, PEDro, Web of Science, Scopus and CENTRAL databases were systematically searched from inception to June 11th, 2020. Read More

View Article and Full-Text PDF

Changes in Treatments and Outcomes After Implementation of a National Universal Access Program for Juvenile Idiopathic Arthritis.

J Rheumatol 2021 May 1. Epub 2021 May 1.

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. Corresponding author: Arturo Borzutzky, M.D., Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362 of. 807, Santiago, Chile 8330077. E-mail:

Objective: To evaluate the clinical and demographic characteristics of patients with juvenile idiopathic arthritis (JIA) in Chile and compare treatments and outcomes before and after the introduction in 2010 of the Explicit Health Guarantees (GES) for JIA, a national universal access program for diagnosis and treatment of this condition.

Methods: The clinical records of 280 patients with JIA followed at a private tertiary academic health network between 2007 and 2018 were reviewed.

Results: Sixty-nine percent of JIA patients were female, mean age at diagnosis was 8. Read More

View Article and Full-Text PDF

Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.

Pediatr Rheumatol Online J 2021 May 1;19(1):62. Epub 2021 May 1.

Department of Pediatrics, Duke University Hospital, Durham, NC, USA.

Background: Inadequate systemic exposure to infliximab (IFX) is associated with treatment failure. This work evaluated factors associated with reduced IFX exposure in children with autoimmune disorders requiring IFX therapy.

Methods: In this single-center cross-sectional prospective study IFX trough concentrations and anti-drug antibodies (ADAs) were measured in serum from children diagnosed with inflammatory bowel disease (IBD) (n = 73), juvenile idiopathic arthritis (JIA) (n = 16), or uveitis (n = 8) receiving maintenance IFX infusions at an outpatient infusion clinic in a tertiary academic pediatric hospital. Read More

View Article and Full-Text PDF

Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.

Pediatr Rheumatol Online J 2021 May 1;19(1):63. Epub 2021 May 1.

Presbyterian Healthcare Services, New Mexico, Albuquerque, USA.

Background: Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with less than half of exposures progressing to a symptomatic state that primarily consists of pulmonary manifestations. Disseminated coccidioidomycosis is exceedingly rare, occurring in fewer than 1 % of symptomatic infections. Read More

View Article and Full-Text PDF

Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline.

Pediatr Rheumatol Online J 2021 May 1;19(1):64. Epub 2021 May 1.

Department of Pediatric Rheumatology and Immunology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building D3, D-48149, Muenster, Germany.

Objective: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of inflammatory joint disorders with a chronic-remitting disease course. Treat-to-target approaches have been proposed but monitoring disease activity and predicting the response to treatment remains challenging.

Methods: We analyzed biomarkers and their relationship to outcome within the first year after JIA diagnosis in the German Inception Cohort of Newly diagnosed patients with JIA (ICON-JIA). Read More

View Article and Full-Text PDF

Unexpected condition in a rare disease: encephalopathy in early-onset sarcoidosis.

Turk J Pediatr 2021 ;63(2):323-328

Department of Pediatric Rheumatology, Erciyes University Faculty of Medicine, Kayseri.

Background: Granulomatous autoinflammatory diseases are monogenic syndromes caused by mutations in the region encoding the nucleotide-binding domain of the nucleotide-binding oligomerization domain-containing 2 gene. Blau syndrome and early-onset sarcoidosis are familial and sporadic forms of the same disease and are very rare. Many organ systems may be involved; however, neurologic involvement is infrequent. Read More

View Article and Full-Text PDF
January 2021

Utilizing ultrasound findings of a single indicator joint to assess non-systemic juvenile idiopathic arthritis.

Pediatr Rheumatol Online J 2021 Apr 29;19(1):60. Epub 2021 Apr 29.

Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.

Background: Musculoskeletal ultrasound (MSUS) has been used worldwide in adult patients with rheumatoid arthritis (RA) but is beginning to play an increasing role in patients with juvenile idiopathic arthritis (JIA). The aim of this study was to investigate the application of MSUS findings of a single indicator joint in JIA to assess the disease activity and classify disease subtype.

Methods: Thirty-five non-systemic JIA patients with a total of 62 visits were retrospectively recruited in this study. Read More

View Article and Full-Text PDF

Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).

Pediatr Rheumatol Online J 2021 Apr 29;19(1):59. Epub 2021 Apr 29.

Emma Children's Hospital, Amsterdam UMC, Pediatric Immunology, Rheumatology and Infectious Diseases, University of Amsterdam, Amsterdam, The Netherlands.

Background: Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) significantly. However, evidence for individual treatment decisions based on serum anti-TNF drug levels and the presence of anti-drug antibodies (ADAbs) in children is scarce. We aimed to assess if anti-TNF drug levels and/or ADAbs influenced physician's treatment decisions in children with JIA. Read More

View Article and Full-Text PDF

Musculoskeletal ultrasound assessment in pediatric knee hypermobility: a case control study.

Pediatr Rheumatol Online J 2021 Apr 29;19(1):58. Epub 2021 Apr 29.

Department of Rheumatology, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA.

Background: While musculoskeletal ultrasound (MSUS) use in pediatric rheumatology is becoming more common, the majority of pediatric MSUS literature continues to focus on ultrasound findings in healthy children and juvenile idiopathic arthritis with little discussion of other musculoskeletal problems that may mimic arthritis such as joint hypermobility. Chronic joint pain related to hypermobility is a common referral to pediatric rheumatology clinics. Our aim is to describe the musculoskeletal ultrasound (MSUS) characteristics of the knee in a population with joint hypermobility and pain in comparison to control participants. Read More

View Article and Full-Text PDF

Different Chronic Disorders That Fall within the Term Juvenile Idiopathic Arthritis.

Life (Basel) 2021 Apr 27;11(5). Epub 2021 Apr 27.

Department Pediatrics I, University of Medicine and Pharmacology "Iuliu Hațieganu", 3400 Cluj-Napoca, Romania.

Juvenile idiopathic arthritis (JIA) represents a significant challenge for pediatricians who intend to diagnose and treat this pathology. The classification criteria for JIA subtypes are rigid and often do not fully satisfy the possibilities of classification in the subtype. The objective of this study was to identify clearer criteria for classifying JIA subtypes. Read More

View Article and Full-Text PDF

Concerted Actions by PIICP, CTXII, and TNF-α in Patients with Juvenile Idiopathic Arthritis.

Biomolecules 2021 Apr 28;11(5). Epub 2021 Apr 28.

Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, ul. Jedności 8, 41-200 Sosnowiec, Poland.

Joint destruction in juvenile idiopathic arthritis (JIA), initiated in the early, preclinical stage of the disease, is diagnosed on the basis of clinical evaluation and radiographic imaging. The determination of circulating cartilage-matrix turnover markers can facilitate the diagnosis and application of better and earlier treatment strategies for JIA. We have shown that 96 JIA patients have elevated levels of procollagen II C-terminal propeptide (PIICP), reflecting the extent of joint cartilage biosynthesis, and C-telopeptide of type II collagen (CTXII), a biomarker of the resorption of this tissue. Read More

View Article and Full-Text PDF

Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study.

J Clin Med 2021 Apr 19;10(8). Epub 2021 Apr 19.

Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Chodzki 4a, 20-093 Lublin, Poland.

There is limited data on the effect of the novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) on pediatric rheumatology. We examined the prevalence of antibodies against SARS-CoV-2 in children with juvenile idiopathic arthritis (JIA) and a negative history of COVID-19 and the correlation of the presence of these antibodies with disease activity measured by juvenile arthritis disease activity score (JADAS). In total, 62 patients diagnosed with JIA, under treatment with various antirheumatic drugs, and 32 healthy children (control group) were included. Read More

View Article and Full-Text PDF

Targeting CCN Proteins in Rheumatoid Arthritis and Osteoarthritis.

Int J Mol Sci 2021 Apr 21;22(9). Epub 2021 Apr 21.

Graduate Institute of Basic Medical Science, Collage of Medicine, China Medical University, Taichung 40402, Taiwan.

The CCN family of matricellular proteins (CYR61/CCN1, CTGF/CCN2, NOV/CCN3 and WISP1-2-3/CCN4-5-6) are essential players in the key pathophysiological processes of angiogenesis, wound healing and inflammation. These proteins are well recognized for their important roles in many cellular processes, including cell proliferation, adhesion, migration and differentiation, as well as the regulation of extracellular matrix differentiation. Substantial evidence implicates four of the proteins (CCN1, CCN2, CCN3 and CCN4) in the inflammatory pathologies of rheumatoid arthritis (RA) and osteoarthritis (OA). Read More

View Article and Full-Text PDF

Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.

Ther Adv Musculoskelet Dis 2021 12;13:1759720X211006963. Epub 2021 Apr 12.

Clinic for Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Germany, Venusberg Campus 1, Bonn 53127, Germany.

Background: Immune checkpoint inhibitors (ICIs) improved cancer therapy by inducing a higher immune system activity. This effect can cause rheumatic immune-related adverse events (rh-irAEs), which have not yet been extensively studied.

Methods: We analysed 437 patients between 2014 and 2019, treated with ipilimumab (anti-CTLA-4) and/or nivolumab (anti-PD-1) or pembrolizumab (anti-PD-1) at the Clinic for Internal Medicine III, Oncology, Haematology and Rheumatology at the University Hospital Bonn, Germany. Read More

View Article and Full-Text PDF

The challenge of early diagnosis of autoimmune lymphoproliferative syndrome in children with suspected autoinflammatory/autoimmune disorders.

Rheumatology (Oxford) 2021 Apr 28. Epub 2021 Apr 28.

Center for Autoinflammatory diseases and Immunodeficiencies, IRCCS G. Gaslini.

Objectives: To test the usefulness of an extended panel of lymphocyte subsets (LS) in combination with Oliveira's diagnostic criteria for the identification of autoimmune lymphoproliferative syndrome (ALPS) in children referred to a pediatric rheumatology center.

Methods: patients referred from 2015 to 2018 to our Rheumatology Unit for an autoimmune or autoinflammatory condition were retrospectively analyzed. Oliveira's required criteria (chronic lymphoproliferation and elevated DNT) were applied as first screening. Read More

View Article and Full-Text PDF

Brucellosis as a cause of hyperferritinemia in systemic arthritis.

Pediatr Int 2021 Apr 27. Epub 2021 Apr 27.

Pediatric Rheumatology Division, Department of Pediatrics, King Abdullah Specialized Children Hospital, King Abdulaziz Medical City, Riyadh, Saudi Arabia.

View Article and Full-Text PDF

Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept.

Pediatr Rheumatol Online J 2021 Apr 26;19(1):55. Epub 2021 Apr 26.

Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.

Background: Alterations in the composition of the fecal microbiota in children with juvenile idiopathic arthritis (JIA) have been observed in several studies, but it has not been determined whether the standard treatment for JIA changes the composition or function of the microbiota. The first-line disease-modifying anti-rheumatic drug for treatment of JIA is usually methotrexate, followed or supplemented by anti-tumor necrosis factor alpha drugs, such as etanercept. The aim of this study was to investigate the effects of methotrexate and etanercept treatments on the fecal microbiota and the fecal short-chain fatty acids (SCFAs) in children with JIA. Read More

View Article and Full-Text PDF

Utility of patient-reported outcomes measurement information system (PROMIS) physical function form in inflammatory myopathy.

Semin Arthritis Rheum 2021 Apr 15;51(3):539-546. Epub 2021 Apr 15.

Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, BST S 727, 3500 Terrace Street Pittsburgh, PA 15261, United States. Electronic address:

Objective: Idiopathic inflammatory myopathies (IIM) are a group of diseases characterized by muscle weakness, which limit activities of daily living. Patient Reported Outcomes Measurement Information System (PROMIS) is a set of outcome measures developed using NIH funding, but has not yet been studied in adult IIM. Currently, the most commonly used PROs in IIM are Health Assessment Questionnaire (HAQ-DI) and SF-36 physical function-10 (PF10), both of which have several limitations. Read More

View Article and Full-Text PDF

Application of systems biology-based in silico tools to optimize treatment strategy identification in Still's disease.

Arthritis Res Ther 2021 Apr 23;23(1):126. Epub 2021 Apr 23.

Novartis, Gran Via de les Corts Catalanes, 764, 08013, Barcelona, Catalonia, Spain.

Background: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD) are manifestations of an autoinflammatory disorder with complex pathophysiology and significant morbidity, together also termed Still's disease. The objective of the current study is to set in silico models based on systems biology and investigate the optimal treat-to-target strategy for Still's disease as a proof-of-concept of the modeling approach.

Methods: Molecular characteristics of Still's disease and data on biological inhibitors of interleukin (IL)-1 (anakinra, canakinumab), IL-6 (tocilizumab, sarilumab), and glucocorticoids as well as conventional disease-modifying anti-rheumatic drugs (DMARDs, methotrexate) were used to construct in silico mechanisms of action (MoA) models by means of Therapeutic Performance Mapping System (TPMS) technology. Read More

View Article and Full-Text PDF

COVID-19 shares clinical features with anti-melanoma differentiation-associated protein 5 positive dermatomyositis and adult Still's disease.

Clin Exp Rheumatol 2021 Apr 8. Epub 2021 Apr 8.

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Objectives: To investigate the similarities and differences between Coronavirus disease 2019 (COVID-19) and autoimmune and autoinflammatory rheumatic diseases characterised by hyperferritinaemia, such as antimelanoma differentiation-associated protein 5 (MDA5) autoantibody-positive dermatomyositis and adult Still's disease.

Methods: We reviewed consecutive, newly diagnosed, untreated patients with COVID-19, anti-MDA5 dermatomyositis, or adult Still's disease. We compared their clinical, laboratory, and radiological characteristics, including the prevalence of macrophage activation syndrome and lung involvement in each disease. Read More

View Article and Full-Text PDF

[Cushing's syndrome with subsequent tertiary adrenocortical insufficiency after simultaneous multiple intra-articular local glucocorticoid treatment : Keep an eye on hormone deficiency conditions requiring treatment after multiple administrations of local steroids].

Z Rheumatol 2021 Apr 22. Epub 2021 Apr 22.

Klinik für Kinder- und Jugendmedizin, Allgemeine Pädiatrie, Universitätsklinikum Münster, Münster, Deutschland.

After simultaneous multiple local treatment with glucocorticoids at 46 sites a 4‑year-old female patient with newly diagnosed polyarticular juvenile idiopathic arthritis (JIA) initially developed Cushing's syndrome followed by a gradual worsening of her condition and finally an acute high fever urinary tract infection. Iatrogenic adrenocortical insufficiency after multiple intra-articular glucocorticoid administration was diagnosed. The possibility of severe systemic glucocorticoid side effects after extensive local treatment should be included in the regular management of JIA patients. Read More

View Article and Full-Text PDF

Development and reliability of a novel ultrasonographic joint-specific scoring system for synovitis with reference atlas for patients with juvenile idiopathic arthritis.

RMD Open 2021 Apr;7(2)

Department of Rheumatology, Oslo University Hospital, Oslo, Norway.

Objective: To develop an ultrasonographic image acquisition protocol and a joint-specific scoring system for synovitis with reference atlas in patients with juvenile idiopathic arthritis (JIA) and to assess the reliability of the system.

Methods: Seven rheumatologists with extensive ultrasound experience developed a scanning protocol and a semiquantitative joint-specific scoring system for B-mode (BM) synovitis for the elbow, wrist, metacarpophalangeal 2-3, proximal interphalangeal 2-3, hip, knee, ankle and metatarsophalangeal 2-3 joints. An ultrasonographic reference atlas for BM synovitis, divided in four age groups (2-4, 5-8, 9-12, 13-18 years), and power Doppler (PD) activity was then developed. Read More

View Article and Full-Text PDF

Correction to: Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.

Paediatr Drugs 2021 Apr 21. Epub 2021 Apr 21.

Division of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, 3225 Eden Ave., Cincinnati, OH, 45267, USA.

View Article and Full-Text PDF

[Therapeutic options in juvenile idiopathic arthritis : Surgical and conservative orthopedic rheumatological treatment].

J-P Haas M Arbogast

Z Rheumatol 2021 Apr 21. Epub 2021 Apr 21.

Abteilung für Rheumaorthopädie und Handchirurgie, Zentrum für Rheumatologie, Orthopädie und Schmerztherapie Klinik Oberammergau, Oberammergau, Deutschland.

The treatment of juvenile idiopathic arthritis (JIA) has made substantial progress within the last 25 years. Modern medicinal treatment enables inflammatory activity of the disease to be controlled in most of the cases. Mutilating courses of disease, which were formerly the rule have now become the exception. Read More

View Article and Full-Text PDF

Nutri-epigenetics: the effect of maternal diet and early nutrition on the pathogenesis of autoimmune diseases.

Minerva Pediatr (Torino) 2021 Apr;73(2):98-110

Unit of Maternal and Child Health, Department of Research, Sidra Medicine, Doha, Qatar -

Autoimmune diseases comprise a wide group of diseases involving a self-response of the immune system against the host. The etiopathogenesis is very complex involving disease-specific factors but also environmental factors, among which the diet. Maternal diet during pregnancy as well as early nutrition recently attracted the interest of the scientists as contributing to the immune programming. Read More

View Article and Full-Text PDF